Later this year, the first US-based clinical trial to test whether an organoid model of prostate cancer can predict drug response will begin recruiting patients. Researchers will grow the organoids—miniorgans coaxed to develop from stem cells—from each patient’s cancer tissues and expose the organoids to the patient’s planned course of therapy. If the organoids mirror patients’ drug responses, the results would support the model’s use as a tool to help guide therapy.
When immune cells infiltrate tumors in large numbers, patients do better. Now researchers aim to harness this immune response to predict outcomes. The Society for Immunotherapy of Cancer (SITC) in Milwaukee is coordinating an international effort to validate Immunoscore, an assay that quantifies this immune response.